Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuCellICCC +4.00%51 EV-to-OCF is 16.22 as of Aug. 20, 2026, which is 42% below its 10-year median of 27.92. GuruFocus rates ICCC with a GF Score™ of 51/100 and a GF Value™ of $6.91 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,409 Biotechnology companies, ImmuCell ranks worse than 86.16% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ImmuCell's Enterprise Value is $95.59 Mil.
ImmuCell's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $5.89 Mil. Therefore, ImmuCell's EV-to-OCF for today is 16.22.
The historical rank and industry rank for ImmuCell's EV-to-OCF or its related term are showing as below:
ICCC'
s EV-to-OCF Range Over the Past 10 Years
Min: -498.57 Med: 27.92 Max: 691.6
Current: 16.22
During the past 13 years, the highest EV-to-OCF of ImmuCell was 691.60. The lowest was -498.57. And the median was 27.92.
ICCC's EV-to-OCF is ranked worse than 86.16% of 1409
companies
in the Biotechnology industry
Industry Median: -3.66
vs ICCC: 16.22
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ImmuCell's share price for today is $10.13.
ImmuCell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ImmuCell EV-to-OCF Related Terms
ImmuCell EV-to-OCF Historical Data
* Premium members only.
The historical data trend for ImmuCell's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ImmuCell's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuCell EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuCell's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ImmuCell's EV-to-OCF falls into.
ImmuCell's current Enterprise Value is $95.59 Mil.
ImmuCell's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuCell (ICCC) has a EV-to-OCF of 16.22 as of Aug. 20, 2026. This is 42% below median its historical median of 27.92. According to the industry distribution chart, ImmuCell ranks #1214 out of 1409 companies in the Biotechnology industry, placing it in the top 86.2%.
Is ImmuCell's EV-to-OCF too high?
ImmuCell's current EV-to-OCF of 16.22 is 42% below median its 10-year median of 27.92. Based on the distribution chart, ImmuCell ranks #1214 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ImmuCell has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's EV-to-OCF compare to COYA and ENTX?
According to the Biotechnology industry distribution chart, ImmuCell ranks #1214 out of 1409 companies for EV-to-OCF. This places ImmuCell in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. ImmuCell's current EV-to-OCF is 16.22, which is 42% below median its own 10-year median of 27.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $10.13 — trading 46.6% above its estimated fair value. The current EV-to-OCF is 16.22, which is 42% below median its 10-year median of 27.92. ImmuCell's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ImmuCell (ICCC), the current EV-to-OCF is 16.22 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmuCell (ICCC) Overvalued in 2026?
Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued.
The current stock price of $10.13 is trading 46.6% above its estimated GF Value™ of $6.91.
GuruFocus considers ImmuCell to be Significantly Overvalued.
Key valuation signals for ICCC:
EV-to-OCF: 16.22 (42% below median its 10-year median of 27.92)
GF Value™: $6.91 vs. price of $10.13 (46.6% above fair value)
No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
51GF Score
Get the complete analysis for ICCC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICCC has been successfully added to your 
